Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.
Allogeneic hematopoietic cell transplantation (alloHCT) represents the only curative therapy for several hematologic malignancies, and shows promise as a nascent treatment modality for select solid tumors. Although the original goal of alloHCT was hematopoietic reconstitution after sub-lethal chemoradiotherapy, recognition of a profound donor lymphocyte-mediated graft-versus-leukemia (GVL) or graft-versus-tumor (GVT) effect has shifted the paradigm from pre-transplant cytoreduction to tumor control via donor lymphocytes. In human leukocyte antigen (HLA)-compatible alloHCT, GVL and GVT reactions are induced primarily by donor T-cell recognition of minor histocompatibility antigens (mHAgs). Here we review the literature regarding mHAg-specific T cells in GVL and GVT reactions, and discuss the prospects of exploiting mHAgs as immunotherapeutic targets.
Feng
Xin
X
Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
Hui
Kwok Min
KM
Younes
Hashem M
HM
Brickner
Anthony G
AG
D000818:Animals; D000939:Epitopes / Q000276:immunology; D020544:Graft vs Leukemia Effect / Q000276:immunology*; D020350:Graft vs Tumor Effect / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D015778:Minor Histocompatibility Antigens / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
D000939:Epitopes; D015778:Minor Histocompatibility Antigens